Logo image of INSM

INSMED INC (INSM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INSM - US4576693075 - Common Stock

161.42 USD
+2.15 (+1.35%)
Last: 1/16/2026, 8:00:02 PM
161.42 USD
0 (0%)
After Hours: 1/16/2026, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to INSM. INSM was compared to 525 industry peers in the Biotechnology industry. The financial health of INSM is average, but there are quite some concerns on its profitability. INSM is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year INSM has reported negative net income.
  • In the past year INSM has reported a negative cash flow from operations.
  • In the past 5 years INSM always reported negative net income.
  • In the past 5 years INSM always reported negative operating cash flow.
INSM Yearly Net Income VS EBIT VS OCF VS FCFINSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

  • INSM has a Return On Assets (-50.15%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -125.20%, INSM is doing worse than 60.76% of the companies in the same industry.
Industry RankSector Rank
ROA -50.15%
ROE -125.2%
ROIC N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INSM Yearly ROA, ROE, ROICINSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • INSM's Gross Margin of 76.54% is amongst the best of the industry. INSM outperforms 84.38% of its industry peers.
  • In the last couple of years the Gross Margin of INSM has remained more or less at the same level.
  • INSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
INSM Yearly Profit, Operating, Gross MarginsINSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

  • INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for INSM has been increased compared to 1 year ago.
  • The number of shares outstanding for INSM has been increased compared to 5 years ago.
  • INSM has a better debt/assets ratio than last year.
INSM Yearly Shares OutstandingINSM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
INSM Yearly Total Debt VS Total AssetsINSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • INSM has an Altman-Z score of 11.02. This indicates that INSM is financially healthy and has little risk of bankruptcy at the moment.
  • INSM has a Altman-Z score of 11.02. This is amongst the best in the industry. INSM outperforms 83.43% of its industry peers.
  • A Debt/Equity ratio of 0.77 indicates that INSM is somewhat dependend on debt financing.
  • INSM has a Debt to Equity ratio of 0.77. This is in the lower half of the industry: INSM underperforms 72.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF N/A
Altman-Z 11.02
ROIC/WACCN/A
WACC8.64%
INSM Yearly LT Debt VS Equity VS FCFINSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

  • A Current Ratio of 4.63 indicates that INSM has no problem at all paying its short term obligations.
  • INSM has a Current ratio (4.63) which is comparable to the rest of the industry.
  • INSM has a Quick Ratio of 4.34. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of INSM (4.34) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.63
Quick Ratio 4.34
INSM Yearly Current Assets VS Current LiabilitesINSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

  • INSM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.53%.
  • Looking at the last year, INSM shows a very strong growth in Revenue. The Revenue has grown by 30.34%.
  • Measured over the past years, INSM shows a very strong growth in Revenue. The Revenue has been growing by 21.65% on average per year.
EPS 1Y (TTM)-11.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.8%
Revenue 1Y (TTM)30.34%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%52.36%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.44% on average over the next years. This is a very strong growth
  • INSM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 67.90% yearly.
EPS Next Y-13.3%
EPS Next 2Y16.29%
EPS Next 3Y21.36%
EPS Next 5Y26.44%
Revenue Next Year47.16%
Revenue Next 2Y85.76%
Revenue Next 3Y83.68%
Revenue Next 5Y67.9%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INSM Yearly Revenue VS EstimatesINSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B 10B
INSM Yearly EPS VS EstimatesINSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 15 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • INSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INSM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INSM Price Earnings VS Forward Price EarningsINSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INSM Per share dataINSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

  • INSM's earnings are expected to grow with 21.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.29%
EPS Next 3Y21.36%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for INSM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INSMED INC

NASDAQ:INSM (1/16/2026, 8:00:02 PM)

After market: 161.42 0 (0%)

161.42

+2.15 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30
Earnings (Next)02-18
Inst Owners99.83%
Inst Owner Change0.04%
Ins Owners0.59%
Ins Owner Change-12.8%
Market Cap34.43B
Revenue(TTM)447.02M
Net Income(TTM)-1.18B
Analysts85.6
Price Target217.87 (34.97%)
Short Float %4.23%
Short Ratio2.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.48%
Min EPS beat(2)-28.87%
Max EPS beat(2)-28.09%
EPS beat(4)0
Avg EPS beat(4)-18.15%
Min EPS beat(4)-28.87%
Max EPS beat(4)-4.46%
EPS beat(8)1
Avg EPS beat(8)-14.89%
EPS beat(12)2
Avg EPS beat(12)-15.58%
EPS beat(16)4
Avg EPS beat(16)-11.73%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)1.43%
Max Revenue beat(2)20.71%
Revenue beat(4)2
Avg Revenue beat(4)5.14%
Min Revenue beat(4)-1.17%
Max Revenue beat(4)20.71%
Revenue beat(8)3
Avg Revenue beat(8)1.76%
Revenue beat(12)4
Avg Revenue beat(12)1.09%
Revenue beat(16)6
Avg Revenue beat(16)1.62%
PT rev (1m)0.25%
PT rev (3m)38.92%
EPS NQ rev (1m)5.96%
EPS NQ rev (3m)-7.93%
EPS NY rev (1m)-1.8%
EPS NY rev (3m)-12.69%
Revenue NQ rev (1m)15.21%
Revenue NQ rev (3m)23.53%
Revenue NY rev (1m)4.48%
Revenue NY rev (3m)12.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 77.01
P/FCF N/A
P/OCF N/A
P/B 36.41
P/tB 47.49
EV/EBITDA N/A
EPS(TTM)-6.19
EYN/A
EPS(NY)-3.62
Fwd EYN/A
FCF(TTM)-4.25
FCFYN/A
OCF(TTM)-4.14
OCFYN/A
SpS2.1
BVpS4.43
TBVpS3.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.15%
ROE -125.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.54%
FCFM N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 139.18%
Cap/Sales 5.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.63
Quick Ratio 4.34
Altman-Z 11.02
F-Score3
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)113.37%
Cap/Depr(5y)86.53%
Cap/Sales(3y)4.8%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.8%
EPS Next Y-13.3%
EPS Next 2Y16.29%
EPS Next 3Y21.36%
EPS Next 5Y26.44%
Revenue 1Y (TTM)30.34%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%52.36%
Revenue Next Year47.16%
Revenue Next 2Y85.76%
Revenue Next 3Y83.68%
Revenue Next 5Y67.9%
EBIT growth 1Y-40.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.59%
EBIT Next 3Y21.51%
EBIT Next 5YN/A
FCF growth 1Y-72.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.7%
OCF growth 3YN/A
OCF growth 5YN/A

INSMED INC / INSM FAQ

Can you provide the ChartMill fundamental rating for INSMED INC?

ChartMill assigns a fundamental rating of 3 / 10 to INSM.


Can you provide the valuation status for INSMED INC?

ChartMill assigns a valuation rating of 1 / 10 to INSMED INC (INSM). This can be considered as Overvalued.


How profitable is INSMED INC (INSM) stock?

INSMED INC (INSM) has a profitability rating of 1 / 10.


What is the financial health of INSMED INC (INSM) stock?

The financial health rating of INSMED INC (INSM) is 5 / 10.